Singh I, Nagiec EE, Thompson JM, Krzyzanski W, Singh P. A systems pharmacology model of erythropoiesis in mice induced by small molecule inhibitor of prolyl hydroxylase enzymes. CPT Pharmacometrics Syst Pharmacol. 2015; 4.
Krzyzanski W. Systems pharmacology models for guiding drug design.. CPT: Pharmacometrics & Systems Pharmacology. 2013; 2.
W. Krzyzanski, M. E. Brier, T. M. Creed, A. E. Gaweda. Reticulocyte-based estimation of red blood cell lifespan. Experimental Hematology. 2013; 41.
Yan X; Ait-Oudhia S; Krzyzanski W. Erythropoietin-induced erythroid precursor pool. Phrmaceutical Research. 2012; 30.
Yan X; Chen Y; Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.. Journal of Pharmacokinetics and Pharmacodynamics. 2012; 39.
Yan X; Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target - mediated drug disposition model.. Journal of pharmacokinetics and pharmacodynamics. 2012; 39.
Krzyzanski W; Perez-Ruixo JJ. Lifespan based indirect response models.. 2012.
Achuthanandam R; Makropoulos D; Johns L; Volk A; Brosnan K; Lu J; Krzyzanski W; Bugelski PJ. Pharmacodynamics of CNTO 530 and darbepoetin-à in human TNF-? transgenic mice, a murine model of anemia of chronic disease.. Pharmacology and Pharmacy. 2011; 2.
Felmlee MA; Krzyzanski W; Morse BL; Morris ME. Use of a Local Sensitivity Analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for ?-Hydroxybutyric Acid. AAPS J.. 2011; 13.
Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38.
Ait-Oudhia S; Vermeulen A; Krzyzanski W. Non-linear mixed effects modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm. Drug Dispos. Biopharmaceutics and Drug Disposition. 2011; 32.
Achuthanandam R; Makropoulos D; Johns L; Volk A; Brosnan K; Lu J; Krzyzanski W; Bugelski P. Pharmacodynamics of CNTO 530 and darbepoetin-à in human TNF-? transgenic mice, a murine model of anemia of chronic disease.. Pharmacology and Pharmacy. 2011; 2.
Yan X; Mager DE; Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.. Journal of Pharmacokinetics and Pharmacodynamics. 2010.
Wang Y; Krzyzanski W; Doshi S; Xiao JJ; Perez-Ruixo JJ; Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.. AAPS Journal. 2010; 12.
Wiczling P; Lowe P; Pigeolet E; Ludicke F; Balser S; Krzyzanski W. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clinical Pharamcokinetics. 2009; 48.
Wiczling P; Aid-Oudhia S; Krzyzanski W. Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry Part A. 2009; 75A.
Marathe A; Krzyzanski W; Mager DE. Numerical Validation and Properties of a Rapid Binding Approximation of a Target-Mediated Drug Disposition Pharmacokinetic Model. J Pharmacokinet Pharmacodyn. 2009; 36.
Krzyzanski W; Perez-Ruixo JJ; Vermeulen A. Basic pharamacodynamic models for agents that alter the lifespan distribution of natural cells. Journal of Pharmacokinetics and Pharmacodynamics. 2008; 35.
Wyska E; Krzyzanski W. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377.
Wiczling P; Krzyzanski W. Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol. 2008; 36.
PAcrez-Ruixo JJ; Hing J; Krzyzanski W. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet. 2008; 47.
Woo S; Krzyzanski W; Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chem. Pharmacol.. 2008; 62.
Woo S; Krzyzanski W; Duliege A; Stead RR; Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J. Clin. Pharmacol.. 2008; 48.
Straubinger RM; Krzyzanski W; Francoforte CM; Qu J. Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.. Anticancer Res.. 2007; 27.
Woo S; Krzyzanski W; Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokin. Pharmacodyn.. 2007; 34.
Wiczling P; Krzyzanski W. Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model.. Cytometry Part A. 2007; 71A.
Krzyzanski W; Bell J. Modelling the geometric features and investigating electrical properties of dendrites in a fish thalamic neuron. Math. Mathematical Medicine and Biology. 2007; 24.
Abraham AK; Krzyzanski W; Mager DE. Partial derivative based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007; 9.
Krzyzanski W; Perez-Ruixo JJ. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.. Pharmaceutical Research. 2007; 24.
Woo S; Krzyzanski W; Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.. Journal of Pharmacology and Experimental Therapeutics. 2006; 319.
Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
Yao Z; Krzyzanski W; Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
Krzyzanski W; Woo S; Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
Jamal NM; Krzyzanski W; Cheung W; Lau CY; Messner MA. Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture.. J. Int. Med. Res.. 2006; 34.
Society for Industrial and Applied Mathematics (2014–present)
International Society of Pharmacometrics (2011–present)
American Association of Pharmaceutical Scientists (1998–present)
"Mathematical and Computational Advances in Pharmacometrics" ACoP 7, ISoP, Symposium (2016)
"Pharmacodynamic models of age-structured cell populations" ACoP 7, ISoP (2016)
"Delay Differential Equations in Pharmacokinetics and Pharmacodynamics" Workshop on Mathematical Pharmacology, Lorentz Center (2015)
"Cell-level Model of Pharmacodynamics Mediated Drug Disposition in Chemotherapy Induced Thrombocytopenia" AstraZeneca’s Modelling and Simulation Symposium, AstraZeneca (2014)
"Role of Pharmacodynamic Response in Clearance of Drugs Targeting Membrane Bound Proteins" 6th Annual Symposium Center for Protein Therapeutics, University at Buffalo (2014)
"A vRNA Structured Population Model of Hepatitis C Virus Dynamics" European Conference on Mathematics and Theoretical Biology, A mini symposium on Modeling Viral Hepatitis Dynamics: From Bench to Bedside (2014)
"Estimability Of Transit Compartments Model Parameters From Steady State PharmacokineticsData" American Confernce on Pharmacometrics, ISoP (2013)
"Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics" American Conference on Pharmacometrics, ISoP (2013)
"Population Modeling Using Complex Physiologically-Based Models" American Conference on Pharmacometrics, International Society for Pharmacometrics (2013)
"Simplification of Complex Physiologically-based Pharmacokinetic Models of Monoclonal Antibodies" American Conference on Pharamcometrics, ISoP (2013)
"Simplification of Complex Physiologically-based Pharmacokinetic Models of Monoclonal Antibodies" AAPS National Biotechnology Conference, AAPS (2013)
"Bridging the Gap Between Systems Pharmacology and PK/PD to Enhance Drug development The case of erythropoiesis-stimulating agents." PKPD Summit IV (2013)
"Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents" ASCPT Annual Meeting 2013, ASCPT (2013)
"Quantitative Prediction of Human PK for mAbs exhibiting Target-mediated Disposition:" ASCPT Annual Meeting 2013, ASCPT (2013)
"Comparisons between corrected and dose-corrected Michaelis-Menton approximations of Target-mediated drug disposition model" AAPS Annual Meeting 2012, AAPS (2012)
"Reticulocyte-Based Estimation of Red Blood Cell Lifespan" American Society of Nephrology Kidney Week, American Society of Nephrology (2012)
"Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor" Population Approach Group Europe (2012)
"Advancements and Applications of Multiscale Systems Pharmacology Modeling" American Conference on Pharmacometrics, American Society of Pharmacometrics (2011)
"Modeling of non-stationary RBC survival: Effect of erythropoietin on RBC mortality vs. production in rats." POPULATION APPROACH GROUP in AUSTRALIA & NEW ZEALAND, University of Auckland (2011)
"Treatment of Anemia with Erythropoietin-Stimulating Agents vs. Cardiovasular Toxicities: A Modeling Perspective." BIT's 8th Annual Congress of 2010 International Drug Discovery Science and Technology, BIT Life Sciences (2010)
"PK/PD Intrigues of the Erythropoietic System" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
"PK/PD Modeling of the Therapeutic Effects of Erythropoietin" Semiparametric Bayesian Inference Summer Program, Statistical and Applied Mathematical Sciences Institute (2010)
"An interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models" Population Approach Group in Europe, Martin-Luther-Universit„t Halle-Wittenberg (2010)
"An Age-Structured Population Model of RBC Survival" 6th International Symposium on Measurement & Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center fof Drug Research (2010)
"Minimal Effective Concentration and Efficacy of Epoetins" Bioequivalence and Bioavailability 2010 Pharmaceutical R&D Summit, OMICS Publishing Group (2010)
"Comparison of Two Mechanisms for Time Dependent Clearance of Recombinant Human Erythropoietin after Multiple Dosing in Rats" AAPS Annual Meeting (2009)
"Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin Following Multiple Dosing in Rats" AAPS Annual Meeting (2009)
"Comparison of Pharmacokinetics of Epoetin Alfa Following Multiple Subcutaneous Administrations in Healthy Volunteers and Anemic Cancer Patients" American Conference on Pharmacometrics (2009)
"Determinants of Erythropoiesis-Stimulating Agent Efficacy: Exposure vs. Potency" 7th International Drug Discovery Science and Technology Annual Congress (2009)
"Modeling and simulations for assessment of pharmacokinetics and pharmacodynamics of a G-CSF biosimilar" American Conference on Pharmacometrics (2009)
"Modeling Drug Effects on the Hematopoietic System" The 4th Annual University at Buffalo/ Pfizer meeting, Pfizer Inc (2009)
"Pharmacodynamic Model of the Tolerance Effect on Blood Reticulocytes After Multiple Dosing of Recombinant Human Erythropoietin in Rats" AAPS Annual Meeting (2008)
"Population Modeling of Filgrastim Pharmacokinetics in Healthy Adults Following Intravenous and Subcutaneous Administrations" AAPS Annual Meeting (2008)
"Selection Between Michaelis-Menten and Target-Mediated Drug Disposition Pharmacokinetic Models" AAPS Annual Meeting, AAPS (2008)
"Validity of the Rapid Binding Approximation of a Target-Mediated Drug Disposition Model" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2008)
"Effect of Recombinant Human Erythropoietin on Reticulocyte Age Distribution and Survival of RBC" Department of Biochemistry Seminar (2008)
"Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin" 2nd World Conference on Magic Bullets (Ehrlich II) (2008)
"Effect of Treatment with rHuEPO on RBC Survival in Normal Wistar and Anemic Belgrade Rats" Workshop on Erythropoietin Receptor (EPO-R) Expression and Function in Non-Hematopoietic Tissues, NIDDK (2008)
"Effect of Treatment with rHuEPO on RBC Survival in Normal Wistar and Anemic Belgrade Rats" Workshop on Erythropoietin Receptor (EPO-R) Expression and Function in Non-Hematopoietic Tissues., NIDDK (2008)
"Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin" European Conference on Mathematical and Theoretical Biology (2008)
"Comparison of homeostatic reticulocyte aging between normal and Belgrade rats using flow cytometry" ASH Annual Meeting (2007)
Internet Assisted Review; National Institutes of Health; Reviewer (2013)
Decanal Review Committee; A Decanal Review Committee (DRC) consisting of 2 faculty members (Dr. M. Morris, Chair, and Dr. W. Krzyzanski) and 2 graduate student members (Dr. B. Morse and Mr. M. Kosloski) has been established by Dean Anderson, School of Pharmacy and Pharmaceutical; Member (2012)
PharmD Outcomes Assessment Committee; Member (2010–present)
Departmental Awards Committee; Member (2009)
Graduate School Grievance Committee; Member (2009)
Graduate Admission Committee; Member (2008)
HSL Faculty Advisory Committee; Member (2007)
SoPPS Admission Committee; Member (2007)
Pharmacology Day; Reviewer
WinNonlin Workshop; Other
In the Media:
370 Kapoor Hall Buffalo, NY 14214-8033 Phone: (716) 645-4847 email@example.com